News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Data on Navidea Biopharmaceuticals (NEOP)’s AZD4694 Presented by the Banner Alzheimer's Institute at the 6th Annual Human Amyloid Imaging Meeting (HAI)


1/20/2012 6:29:55 AM

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) today announced that the Banner Alzheimer’s Institute, Phoenix, AZ, made two presentations of results from an AstraZeneca-sponsored study on the assessment of Navidea’s late-stage radiopharmaceutical imaging candidate, AZD4694, at the 6th Annual Human Amyloid Imaging Meeting (HAI), in Miami, FL. In December 2011, Navidea in-licensed the worldwide exclusive rights to AZD4694 from AstraZeneca, now being developed by Navidea as a radiopharmaceutical agent for the detection of cerebral amyloid in Alzheimer’s disease (AD) patients.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES